7 completed, 2 terminated. 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 7, Terminated 2 |
Follow vanutide cridificar: new trials by email Literature Review of vanutide cridificar trials Research Report on vanutide cridificar
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease ACC-001 3 μg/ QS-21 50 μg, ACC-001 10 μg/ QS-21 50 μg, Placebo- Phosphate buffered saline (PBS) - Alzheimer's Disease | Phase 2 | Completed | Pfizer | 63 | 2011-02-01 | 2016-02-25 |
| Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease ACC-001 (vanutide cridificar) - Alzheimer's Disease | Phase 2 | Completed | JANSSEN Alzheimer Immunotherapy Research & Development, LLC | 126 | 2011-01-01 | 2015-01-05 |
| Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease ACC-001 - Alzheimer's Disease | Phase 2 | Terminated | Pfizer | 53 | 2010-12-01 | 2014-12-22 |
| Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease ACC-001(3µg) + QS21, ACC-001(10µg) + QS21, ACC-001(30µg) + QS21 - Alzheimer Disease | Phase 2 | Completed | Pfizer | 160 | 2009-11-05 | 2021-03-25 |
| Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease ACC-001, QS-21 - Alzheimer's Disease | Phase 2 | Completed | Pfizer | 32 | 2009-08-01 | 2016-01-01 |
| A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease ACC-001+ QS21 (3mcg), ACC-001 (10 mcg) + QS-21, ACC-001+QS-21 (30mcg) - Alzheimer Disease | Phase 2 | Terminated | Pfizer | 160 | 2009-07-01 | 2016-04-01 |
| Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease ACC-001, QS-21, PBS - Alzheimer Disease | Phase 2 | Completed | Pfizer | 40 | 2008-12-01 | 2016-01-01 |
| Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease ACC-001 + QS-21, QS-21, Diluent: Phosphate Buffered Saline - Alzheimer Disease | Phase 2 | Completed | Pfizer | 160 | 2007-11-01 | 2016-01-01 |
| Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease ACC-001 + QS-21, ACC-001, QS-21 - Alzheimer Disease | Phase 2 | Completed | Pfizer | 86 | 2007-05-01 | 2016-01-01 |
Pfizer (8) · JANSSEN Alzheimer Immunotherapy Research & Development, LLC (1)
United States (4) · Japan (3) · France (2) · Germany (2) · Spain (2)
PMID 25731629, PMID 26967206, PMID 29199321, PMID 29210443
2009 (1)